Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

The emerging roles of DOT1L in leukemia and normal development.

McLean CM, Karemaker ID, van Leeuwen F.

Leukemia. 2014 Nov;28(11):2131-8. doi: 10.1038/leu.2014.169. Epub 2014 May 23. Review.

PMID:
24854991
2.

DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.

Chen CW, Koche RP, Sinha AU, Deshpande AJ, Zhu N, Eng R, Doench JG, Xu H, Chu SH, Qi J, Wang X, Delaney C, Bernt KM, Root DE, Hahn WC, Bradner JE, Armstrong SA.

Nat Med. 2015 Apr;21(4):335-43. doi: 10.1038/nm.3832. Epub 2015 Mar 30.

3.

DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.

Nguyen AT, Taranova O, He J, Zhang Y.

Blood. 2011 Jun 23;117(25):6912-22. doi: 10.1182/blood-2011-02-334359. Epub 2011 Apr 26.

4.

Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.

Chen CW, Armstrong SA.

Exp Hematol. 2015 Aug;43(8):673-84. doi: 10.1016/j.exphem.2015.05.012. Epub 2015 Jun 25. Review.

5.

Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.

Feng Z, Yao Y, Zhou C, Chen F, Wu F, Wei L, Liu W, Dong S, Redell M, Mo Q, Song Y.

J Hematol Oncol. 2016 Mar 12;9:24. doi: 10.1186/s13045-016-0252-7.

6.

Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation.

Jo SY, Granowicz EM, Maillard I, Thomas D, Hess JL.

Blood. 2011 May 5;117(18):4759-68. doi: 10.1182/blood-2010-12-327668. Epub 2011 Feb 25.

7.

MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.

Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L, Pollock RM, Richon VM, Kung AL, Armstrong SA.

Cancer Cell. 2011 Jul 12;20(1):66-78. doi: 10.1016/j.ccr.2011.06.010.

8.

DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.

Liu W, Deng L, Song Y, Redell M.

PLoS One. 2014 May 23;9(5):e98270. doi: 10.1371/journal.pone.0098270. eCollection 2014.

9.

Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.

Deshpande AJ, Chen L, Fazio M, Sinha AU, Bernt KM, Banka D, Dias S, Chang J, Olhava EJ, Daigle SR, Richon VM, Pollock RM, Armstrong SA.

Blood. 2013 Mar 28;121(13):2533-41. doi: 10.1182/blood-2012-11-465120. Epub 2013 Jan 29.

10.
11.

Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.

Wang E, Kawaoka S, Yu M, Shi J, Ni T, Yang W, Zhu J, Roeder RG, Vakoc CR.

Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3901-6. doi: 10.1073/pnas.1301045110. Epub 2013 Feb 14.

12.

The upstreams and downstreams of H3K79 methylation by DOT1L.

Vlaming H, van Leeuwen F.

Chromosoma. 2016 Sep;125(4):593-605. doi: 10.1007/s00412-015-0570-5. Epub 2016 Jan 4. Review.

PMID:
26728620
13.

The diverse functions of Dot1 and H3K79 methylation.

Nguyen AT, Zhang Y.

Genes Dev. 2011 Jul 1;25(13):1345-58. doi: 10.1101/gad.2057811. Review.

14.

A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.

Anglin JL, Song Y.

J Med Chem. 2013 Nov 27;56(22):8972-83. doi: 10.1021/jm4007752. Epub 2013 Aug 14. Review.

15.

The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure.

Jones B, Su H, Bhat A, Lei H, Bajko J, Hevi S, Baltus GA, Kadam S, Zhai H, Valdez R, Gonzalo S, Zhang Y, Li E, Chen T.

PLoS Genet. 2008 Sep 12;4(9):e1000190. doi: 10.1371/journal.pgen.1000190.

16.

The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target.

Wong M, Polly P, Liu T.

Am J Cancer Res. 2015 Aug 15;5(9):2823-37. eCollection 2015.

17.

DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells.

Steger DJ, Lefterova MI, Ying L, Stonestrom AJ, Schupp M, Zhuo D, Vakoc AL, Kim JE, Chen J, Lazar MA, Blobel GA, Vakoc CR.

Mol Cell Biol. 2008 Apr;28(8):2825-39. doi: 10.1128/MCB.02076-07. Epub 2008 Feb 19.

18.

Targeting epigenetic programs in MLL-rearranged leukemias.

Bernt KM, Armstrong SA.

Hematology Am Soc Hematol Educ Program. 2011;2011:354-60. doi: 10.1182/asheducation-2011.1.354. Review.

PMID:
22160057
19.

Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development.

Barry ER, Corry GN, Rasmussen TP.

Expert Opin Ther Targets. 2010 Apr;14(4):405-18. doi: 10.1517/14728221003623241. Review.

PMID:
20230194
20.

Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential.

Kuntimaddi A, Achille NJ, Thorpe J, Lokken AA, Singh R, Hemenway CS, Adli M, Zeleznik-Le NJ, Bushweller JH.

Cell Rep. 2015 May 5;11(5):808-20. doi: 10.1016/j.celrep.2015.04.004. Epub 2015 Apr 23.

Supplemental Content

Support Center